# Bio-Rad Laboratories, Inc.: financial statements, quarterly

BIO · NYSE · CIK 12208 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bio.md) · [Financials](/companies/bio/financials.md) · [Filings](/companies/bio/filings.md) · [Insiders](/companies/bio/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bio/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [632](/filings/0000012208-24-000063.md) | [681](/filings/0000012208-25-000007.md) | [611](/filings/0000012208-25-000026.md) | [639](/filings/0000012208-25-000052.md) | [650](/filings/0000012208-25-000077.md) | [668](/filings/0000012208-25-000007.md) | [585](/filings/0000012208-26-000035.md) | [652](/filings/0000012208-26-000048.md) | [653](/filings/0000012208-25-000077.md) | [693 d](/filings/0000012208-26-000010.md) | [592](/filings/0000012208-26-000035.md) | [651](/filings/0000012208-26-000048.md) |
| Cost of revenue | $m | [296](/filings/0000012208-24-000063.md) | [315 d](/filings/0000012208-26-000010.md) | [285](/filings/0000012208-25-000026.md) | [283](/filings/0000012208-25-000052.md) | [294](/filings/0000012208-25-000077.md) | [326 d](/filings/0000012208-26-000010.md) | [279](/filings/0000012208-26-000035.md) | [306](/filings/0000012208-26-000048.md) | [310](/filings/0000012208-25-000077.md) | [348 d](/filings/0000012208-26-000010.md) | [283](/filings/0000012208-26-000035.md) | [305](/filings/0000012208-26-000048.md) |
| Gross profit | $m | [336](/filings/0000012208-25-000007.md) | [366](/filings/0000012208-25-000007.md) | [326](/filings/0000012208-25-000026.md) | [355](/filings/0000012208-25-000052.md) | [356](/filings/0000012208-25-000077.md) | [342](/filings/0000012208-25-000007.md) | [306](/filings/0000012208-26-000035.md) | [345](/filings/0000012208-26-000048.md) | [343](/filings/0000012208-25-000077.md) | [345 d](/filings/0000012208-26-000010.md) | [309](/filings/0000012208-26-000035.md) | [346](/filings/0000012208-26-000048.md) |
| Research and development | $m | [43.5](/filings/0000012208-24-000063.md) | [63.9 d](/filings/0000012208-26-000010.md) | [66.4](/filings/0000012208-25-000026.md) | [58.9](/filings/0000012208-25-000052.md) | [91.0](/filings/0000012208-25-000077.md) | [79.6 d](/filings/0000012208-26-000010.md) | [73.5](/filings/0000012208-26-000035.md) | [60.5](/filings/0000012208-26-000048.md) | [71.3](/filings/0000012208-25-000077.md) | [70.3 d](/filings/0000012208-26-000010.md) | [62.9](/filings/0000012208-26-000035.md) | [61.2](/filings/0000012208-26-000048.md) |
| Selling, general and administrative | $m | [201](/filings/0000012208-24-000063.md) | [207 d](/filings/0000012208-26-000010.md) | [215](/filings/0000012208-25-000026.md) | [195](/filings/0000012208-25-000052.md) | [200](/filings/0000012208-25-000077.md) | [204 d](/filings/0000012208-26-000010.md) | [209](/filings/0000012208-26-000035.md) | [208](/filings/0000012208-26-000048.md) | [207](/filings/0000012208-25-000077.md) | [221 d](/filings/0000012208-26-000010.md) | [212](/filings/0000012208-26-000035.md) | [212](/filings/0000012208-26-000048.md) |
| Operating income | $m | [90.9](/filings/0000012208-24-000063.md) | [95.3 d](/filings/0000012208-26-000010.md) | [44.6](/filings/0000012208-25-000026.md) | [102](/filings/0000012208-25-000052.md) | [64.5](/filings/0000012208-25-000077.md) | [58.3 d](/filings/0000012208-26-000010.md) | [23.7](/filings/0000012208-26-000035.md) | [77.1](/filings/0000012208-26-000048.md) | [65.3](/filings/0000012208-25-000077.md) | [(119) d](/filings/0000012208-26-000010.md) | [34.1](/filings/0000012208-26-000035.md) | [72.6](/filings/0000012208-26-000048.md) |
| Interest expense | $m | [12.4](/filings/0000012208-24-000063.md) | [12.3 d](/filings/0000012208-26-000010.md) | [12.3](/filings/0000012208-25-000026.md) | [12.3](/filings/0000012208-25-000052.md) | [12.1](/filings/0000012208-25-000077.md) | [12.2 d](/filings/0000012208-26-000010.md) | [12.0](/filings/0000012208-26-000035.md) | [12.6](/filings/0000012208-26-000048.md) | [12.3](/filings/0000012208-25-000077.md) | [12.1 d](/filings/0000012208-26-000010.md) | [12.3](/filings/0000012208-26-000035.md) | [12.1](/filings/0000012208-26-000048.md) |
| Income tax | $m | [30.8](/filings/0000012208-24-000063.md) | [78.7 d](/filings/0000012208-26-000010.md) | [107](/filings/0000012208-25-000026.md) | [(621)](/filings/0000012208-25-000052.md) | [208](/filings/0000012208-25-000077.md) | [(193) d](/filings/0000012208-26-000010.md) | [19.4](/filings/0000012208-26-000035.md) | [96.2](/filings/0000012208-26-000048.md) | [(89.2)](/filings/0000012208-25-000077.md) | [209 d](/filings/0000012208-26-000010.md) | [(163)](/filings/0000012208-26-000035.md) | [171](/filings/0000012208-26-000048.md) |
| Net income | $m | [106](/filings/0000012208-25-000007.md) | [350](/filings/0000012208-25-000007.md) | [384](/filings/0000012208-25-000077.md) | [(2,166)](/filings/0000012208-25-000077.md) | [653](/filings/0000012208-25-000077.md) | [(716)](/filings/0000012208-25-000007.md) | [64.0](/filings/0000012208-26-000048.md) | [318](/filings/0000012208-26-000048.md) | [(342)](/filings/0000012208-25-000077.md) | [720 d](/filings/0000012208-26-000010.md) | [(527)](/filings/0000012208-26-000048.md) | [371](/filings/0000012208-26-000048.md) |
| Diluted EPS | $ per share | [3.64](/filings/0000012208-25-000007.md) | [12.14](/filings/0000012208-25-000007.md) | [13.45](/filings/0000012208-25-000026.md) | [(76.26)](/filings/0000012208-25-000052.md) | [23.34](/filings/0000012208-25-000077.md) | [(25.57)](/filings/0000012208-25-000007.md) | [2.29](/filings/0000012208-26-000035.md) | [11.67](/filings/0000012208-26-000048.md) | [(12.70)](/filings/0000012208-25-000077.md) | not reported | [(19.55)](/filings/0000012208-26-000035.md) | [13.85](/filings/0000012208-26-000048.md) |
| Basic EPS | $ per share | [3.65](/filings/0000012208-25-000007.md) | [12.15](/filings/0000012208-25-000007.md) | [13.46](/filings/0000012208-25-000026.md) | [(76.26)](/filings/0000012208-25-000052.md) | [23.37](/filings/0000012208-25-000077.md) | [(25.57)](/filings/0000012208-25-000007.md) | [2.29](/filings/0000012208-26-000035.md) | [11.67](/filings/0000012208-26-000048.md) | [(12.70)](/filings/0000012208-25-000077.md) | not reported | [(19.55)](/filings/0000012208-26-000035.md) | [13.89](/filings/0000012208-26-000048.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.5](/filings/0000012208-24-000063.md) | [0.4](/filings/0000012208-26-000010.md) | [0.4](/filings/0000012208-25-000026.md) | [0.4](/filings/0000012208-25-000052.md) | [0.4](/filings/0000012208-25-000077.md) | [0.5](/filings/0000012208-26-000010.md) | [0.5](/filings/0000012208-26-000035.md) | [0.4](/filings/0000012208-26-000048.md) | [0.4](/filings/0000012208-25-000077.md) | [0.5](/filings/0000012208-26-000048.md) | [0.5](/filings/0000012208-26-000035.md) | [0.5](/filings/0000012208-26-000048.md) |
| Current assets | $bn | [3.1](/filings/0000012208-23-000072.md) | [3.0](/filings/0000012208-25-000007.md) | [3.1](/filings/0000012208-24-000039.md) | [3.1](/filings/0000012208-24-000052.md) | [3.1](/filings/0000012208-24-000063.md) | [3.0](/filings/0000012208-26-000010.md) | [3.0](/filings/0000012208-25-000026.md) | [2.8](/filings/0000012208-25-000052.md) | [2.8](/filings/0000012208-25-000077.md) | [2.9](/filings/0000012208-26-000048.md) | [2.9](/filings/0000012208-26-000035.md) | [3.0](/filings/0000012208-26-000048.md) |
| Total assets | $bn | [11.9](/filings/0000012208-23-000072.md) | [12.3](/filings/0000012208-25-000007.md) | [12.6](/filings/0000012208-24-000039.md) | [9.7](/filings/0000012208-24-000052.md) | [10.6](/filings/0000012208-24-000063.md) | [9.4](/filings/0000012208-26-000010.md) | [9.5](/filings/0000012208-25-000026.md) | [10.2](/filings/0000012208-25-000052.md) | [9.7](/filings/0000012208-25-000077.md) | [10.6](/filings/0000012208-26-000048.md) | [9.8](/filings/0000012208-26-000035.md) | [10.3](/filings/0000012208-26-000048.md) |
| Current liabilities | $bn | [0.6](/filings/0000012208-23-000072.md) | [0.5](/filings/0000012208-25-000007.md) | [0.5](/filings/0000012208-24-000039.md) | [0.5](/filings/0000012208-24-000052.md) | [0.5](/filings/0000012208-24-000063.md) | [0.5](/filings/0000012208-26-000010.md) | [0.5](/filings/0000012208-25-000026.md) | [0.5](/filings/0000012208-25-000052.md) | [0.5](/filings/0000012208-25-000077.md) | [0.5](/filings/0000012208-26-000048.md) | [0.9](/filings/0000012208-26-000035.md) | [1.0](/filings/0000012208-26-000048.md) |
| Total liabilities | $bn | [3.5](/filings/0000012208-23-000072.md) | [3.6](/filings/0000012208-25-000007.md) | [3.6](/filings/0000012208-24-000039.md) | [2.9](/filings/0000012208-24-000052.md) | [3.1](/filings/0000012208-24-000063.md) | [2.8](/filings/0000012208-26-000010.md) | [2.8](/filings/0000012208-25-000026.md) | [3.1](/filings/0000012208-25-000052.md) | [3.0](/filings/0000012208-25-000077.md) | [3.1](/filings/0000012208-26-000048.md) | [2.9](/filings/0000012208-26-000035.md) | [3.1](/filings/0000012208-26-000048.md) |
| Long-term debt | $bn | [1.2](/filings/0000012208-23-000072.md) | [1.2](/filings/0000012208-25-000007.md) | [1.2](/filings/0000012208-24-000039.md) | [1.2](/filings/0000012208-24-000052.md) | [1.2](/filings/0000012208-24-000063.md) | [1.2](/filings/0000012208-26-000010.md) | [1.2](/filings/0000012208-25-000026.md) | [1.2](/filings/0000012208-25-000052.md) | [1.2](/filings/0000012208-25-000077.md) | [1.2](/filings/0000012208-26-000048.md) | [0.8](/filings/0000012208-26-000035.md) | [0.8](/filings/0000012208-26-000048.md) |
| Current portion of debt | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $bn | [8.4](/filings/0000012208-24-000063.md) | [8.7](/filings/0000012208-26-000010.md) | [9.1](/filings/0000012208-25-000077.md) | [6.8](/filings/0000012208-25-000077.md) | [7.5](/filings/0000012208-25-000077.md) | [6.6](/filings/0000012208-26-000048.md) | [6.7](/filings/0000012208-26-000048.md) | [7.1](/filings/0000012208-26-000048.md) | [6.7](/filings/0000012208-25-000077.md) | [7.5](/filings/0000012208-26-000048.md) | [6.9](/filings/0000012208-26-000048.md) | [7.2](/filings/0000012208-26-000048.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [97.7 d](/filings/0000012208-24-000063.md) | [81.0 d](/filings/0000012208-26-000010.md) | [69.8](/filings/0000012208-25-000026.md) | [97.6 d](/filings/0000012208-25-000052.md) | [164 d](/filings/0000012208-25-000077.md) | [124 d](/filings/0000012208-26-000010.md) | [130](/filings/0000012208-26-000035.md) | [117 d](/filings/0000012208-26-000048.md) | [121 d](/filings/0000012208-25-000077.md) | [165 d](/filings/0000012208-26-000010.md) | [108](/filings/0000012208-26-000035.md) | [98.7 d](/filings/0000012208-26-000048.md) |
| Capital expenditure | $m | [44.1 d](/filings/0000012208-24-000063.md) | [42.3 d](/filings/0000012208-26-000010.md) | [40.2](/filings/0000012208-25-000026.md) | [42.3 d](/filings/0000012208-25-000052.md) | [40.2 d](/filings/0000012208-25-000077.md) | [42.9 d](/filings/0000012208-26-000010.md) | [34.4](/filings/0000012208-26-000035.md) | [45.7 d](/filings/0000012208-26-000048.md) | [31.7 d](/filings/0000012208-25-000077.md) | [45.8 d](/filings/0000012208-26-000010.md) | [30.0](/filings/0000012208-26-000035.md) | [32.0 d](/filings/0000012208-26-000048.md) |
| Share repurchases | $m | [21.3 d](/filings/0000012208-24-000063.md) | [200 d](/filings/0000012208-26-000010.md) | [4.7](/filings/0000012208-25-000026.md) | [101 d](/filings/0000012208-25-000052.md) | [97.9 d](/filings/0000012208-25-000077.md) | [0.0 d](/filings/0000012208-26-000010.md) | [102](/filings/0000012208-26-000035.md) | [140 d](/filings/0000012208-26-000048.md) | [53.4 d](/filings/0000012208-25-000077.md) | [0.0 d](/filings/0000012208-26-000010.md) | [47.8](/filings/0000012208-26-000035.md) | [31.5 d](/filings/0000012208-26-000048.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [29.7](/filings/0000012208-23-000072.md) | [29.7](/filings/0000012208-24-000039.md) | [29.4](/filings/0000012208-24-000052.md) | [29.2](/filings/0000012208-24-000063.md) | [28.5](/filings/0000012208-25-000026.md) | [28.4](/filings/0000012208-25-000052.md) | [28.0](/filings/0000012208-25-000077.md) | [28.0](/filings/0000012208-26-000035.md) | [27.2](/filings/0000012208-26-000048.md) | [26.9](/filings/0000012208-25-000077.md) | [27.0](/filings/0000012208-26-000035.md) | [26.8](/filings/0000012208-26-000048.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 27,668,031 at 2010-06-30, from the cover of the [10-Q filed 2010-08-06](/filings/0000012208-10-000097.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:17 ET. No prices; not investment advice.